Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab

Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Aiyin, Hwang, Thomas N, Phan, Laura T., McCulley, Timothy J., Yoon, Michael K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519137/
https://www.ncbi.nlm.nih.gov/pubmed/23248552
http://dx.doi.org/10.4103/0974-9233.102770
_version_ 1782252639751241728
author Chen, Aiyin
Hwang, Thomas N
Phan, Laura T.
McCulley, Timothy J.
Yoon, Michael K.
author_facet Chen, Aiyin
Hwang, Thomas N
Phan, Laura T.
McCulley, Timothy J.
Yoon, Michael K.
author_sort Chen, Aiyin
collection PubMed
description Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.
format Online
Article
Text
id pubmed-3519137
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-35191372012-12-17 Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab Chen, Aiyin Hwang, Thomas N Phan, Laura T. McCulley, Timothy J. Yoon, Michael K. Middle East Afr J Ophthalmol Case Report Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3519137/ /pubmed/23248552 http://dx.doi.org/10.4103/0974-9233.102770 Text en Copyright: © Middle East African Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Chen, Aiyin
Hwang, Thomas N
Phan, Laura T.
McCulley, Timothy J.
Yoon, Michael K.
Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab
title Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab
title_full Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab
title_fullStr Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab
title_full_unstemmed Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab
title_short Long-Term Management of Orbital and Systemic Reactive Lymphoid Hyperplasia with Rituximab
title_sort long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519137/
https://www.ncbi.nlm.nih.gov/pubmed/23248552
http://dx.doi.org/10.4103/0974-9233.102770
work_keys_str_mv AT chenaiyin longtermmanagementoforbitalandsystemicreactivelymphoidhyperplasiawithrituximab
AT hwangthomasn longtermmanagementoforbitalandsystemicreactivelymphoidhyperplasiawithrituximab
AT phanlaurat longtermmanagementoforbitalandsystemicreactivelymphoidhyperplasiawithrituximab
AT mcculleytimothyj longtermmanagementoforbitalandsystemicreactivelymphoidhyperplasiawithrituximab
AT yoonmichaelk longtermmanagementoforbitalandsystemicreactivelymphoidhyperplasiawithrituximab

Ejemplares similares